Marshall Wace’s Jasper Therapeutics JSPR Stock Holding History

Marshall Wace’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,656	Closed	-$40.2K	–	3451
2026 Q1	$40.2K	Buy	+45,656	New	+$63.4K	﹤0.01%	3000
2025 Q3	–	Sell	-50,686	Closed	-$281K	–	3152
2025 Q2	$281K	Buy	+50,686	New	+$250K	﹤0.01%	2347
2025 Q1	–	Sell	-77,722	Closed	-$1.66M	–	2873
2024 Q4	$1.66M	Buy	77,722 +11,397	+17%	+$237K	﹤0.01%	1521
2024 Q3	$1.25M	Buy	+66,325	New	+$1.32M	﹤0.01%	1558
2024 Q2	–	Sell	-13,449	Closed	-$395K	–	2744
2024 Q1	$395K	Buy	+13,449	New	+$239K	﹤0.01%	2019

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace's JSPR Position: Q2 2026 in Review

Marshall Wace sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 45,656 shares — an estimated $40.2K sold.

Marshall Wace first reported a position in JSPR in Q1 2024 and held it in 5 quarters. The position peaked at $1.66M in Q4 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Marshall Wace reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 45,656 Jasper Therapeutics shares in Q2 2026, an estimated $40.2K.
Marshall Wace first reported a position in Jasper Therapeutics in Q1 2024 and held it in 5 quarters.
Marshall Wace's Jasper Therapeutics position peaked at $1.66M in Q4 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.